crystallization papers
Expression, purification and preliminary X-ray
of a ketoreductase from a type II polyketide synthaseaMolecular Recognition Centre, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, England, bOrganic and Biological Chemistry, School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, England, cDepartment of Biochemistry, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, England, and dDepartment of Pathology and Microbiology, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, England
*Correspondence e-mail: a.t.hadfield@bris.ac.uk
Polyketide metabolites produced by bacteria and other organisms include antibiotics, anticancer and antifungal compounds. In type II polyketide synthesis, three enzymes are sufficient to form a polyketide product of the requisite chain length, although the fidelity of the first Streptomyces coelicolor actIII ORF5 gene that codes for the ketoreductase. The 261-amino-acid protein has been overexpressed with a 20-residue His tag, purified by and crystallized in P3221, with unit-cell parameters a = b = 103.9, c = 123.1 Å. The crystals diffract to 2.5 Å resolution. A complete data set has been collected and structure solution and is under way.
is variable. Addition of ketoreductase (KR) to this system results in the formation of a product with correct and reduction. This paper reports the cloning of the1. Introduction
, 1997; Staunton & Weissman, 2001). These natural products are of enormous pharmaceutical interest and include oxytetracycline (an antibiotic), doxorubicin (anticancer) and resveratrol (antifungal). The polyketide synthase (PKS) biosynthetic complex is organized as either a covalent (type I) or non-covalent (type II) assembly of catalytic domains analogous to fatty-acid synthases (FASs). Both polyketide and fatty-acid biosyntheses proceed via the iterative decarboxylative condensation of malonyl extender units to a starter unit, which is usually acetate.
are a chemically diverse group of produced by bacteria, fungi, plants and marine organisms (Hopwood, 1990In type II PKSs, the minimal number of enzymes required to form a polyketide of the requisite chain length are the ketosynthase (KSα), chain-length factor (KSβ) and the acyl-carrier protein (ACP) (McDaniel et al., 1994, 1995). The KR is the first enzyme to modify the nascent polyketide chain, its primary function being to reduce the carbonyl group at C-9. KR may also enhance the efficiency of the aldol condensation between C-7 and C-12 which is necessary to form the first aromatic ring correctly, since addition of the act KR to the minimal PKS eliminates incorrectly cyclized products (Fu et al., 1994a,b; Fu, Ebert-Khosla et al., 1994).
To date, only four type II aromatic PKS components have been solved. These are three solution NMR structures of the act (Crump et al., 1997), otc (Findlow et al., 2003) and fren (Li et al., 2003) ACPs and a of the unusual priming β-ketosynthase from the R1128 polyketide-biosynthetic pathway (Pan et al., 2002). There is currently no three-dimensional structure of a polyketide type II ketoreductase or indeed any other downstream enzyme from these pathways. The act KR (29 kDa, 261 amino acids) is a member of the short-chain dehydrogenase/reductase evolutionary family of NADP(H) dependent enzymes that contains over 60 genes in the human genome alone (Jornvall et al., 1995; Oppermann et al., 2001, 2003; Kallberg et al., 2002).
2. Materials and methods
2.1. Cloning and expression
The Streptomyces coelicolor actIII ORF5 gene was cloned from genomic DNA isolated from the organism by PCR amplification using primers that added an NdeI restriction site at the N-terminus and a HindIII site at the C-terminus. The restriction sites were digested and the gene was first ligated into the commercial vector pET26b (Novagen). Following successful sequencing, the gene was excised from this non-tagged vector by a restriction digest using NdeI and XhoI (inherent to pET26b). The same restriction sites were used to insert the gene into the plasmid pET15b to incorporate an N-terminal His6 tag at the N-terminus, which results in a total of 20 additional residues (MGSSHHHHHHSSGLVPRGSH). This plasmid was transformed into Escherichia coli strain BL21(DE3) for IPTG-induced expression. Cultures were produced by inoculation of single colonies from LB agar plates (1 ml). These precultures were grown overnight at 310 K. Overnight cultures were then used to typically inoculate 0.5–1 l of LB liquid media. These were grown at 310 K to an A595 of between 0.6 and 0.8. Cultures were then induced by adding IPTG to a final concentration of 1 mM. The cells were disrupted by sonication in 3 × 30 s bursts. The cell debris was removed by centrifugation at 6000g for 30 min. The fully active enzyme was purified from the cell extract in a single step by on an Ni2+ column (Novagen). Fractions containing KR were desalted into buffer A (100 mM phosphate, 10% glycerol pH 7.2) by FPLC and stored at 193 K.
The activity assay was performed by adding ketoreductase, NADPH (cofactor) and malonyl CoA (substrate) to the PKS minimal system. Typically, the assay contained 50 µM ACP, 1 µM KS/CLF, 10 µM KR, 0.1 mM DTT, 2 mM EDTA, 1 mM malonyl CoA, 2 mM NADPH and 10% glycerol, buffered with 0.1 mM KH2PO4 pH 7.3 in a final volume of 100 µl. Polyketide metabolites were extracted with ethyl acetate, freeze-dried and dissolved in methanol for HPLC analysis. The presence of mutactin was used to confirm the presence of active KR.
2.2. Crystallization and data collection
The protein was concentrated to 10 mg ml−1 in 50 mM phosphate buffer pH 8 with 10% glycerol. Comparison with other SDR structures suggests that the ketoreductase oligomeric state is likely to be tetrameric. This was investigated by native PAGE (Fig. 1). In the absence of NADPH, the enzyme appears to exist in a mixture of oligomeric states (tetramer, dimer and monomer). Addition of NADPH to the enzyme under otherwise identical conditions results in a tight band representing the tetramer. NADP+ was therefore added to the concentrated protein, which reduced the phosphate concentration and also ensured that the enzyme existed in the holo form and in a homogenous oligomeric state. The mother liquor used for crystallization contained 5 mg ml−1 protein and 5 mM NADP+ in 25 mM phosphate buffer pH 8 with 10%(v/v) glycerol. Crystallization conditions were identified using a sparse-matrix screen (MDL Screen I and II) using hanging-drop vapour diffusion at 291 K. Data were collected from crystals obtained from wells containing 4.0–4.4 M sodium formate and 10%(v/v) glycerol after combination of equal volumes of reservoir and mother liquor to form 3 µl hanging drops. The crystals belong to P3221, with unit-cell parameters a = b = 103.9, c = 123.1 Å, α = β = 90.0, γ = 120.0°. The small (0.1 × 0.05 × 0.05 mm) gem-like crystals were transferred briefly into a cryoprotectant made up of 25%(v/v) glycerol and 75%(v/v) well solution prior to flash-cooling directly in the nitrogen-gas stream. Diffraction data that were 100% complete to 2.5 Å resolution were collected at 100 K using synchrotron radiation at station 14.2 at the Daresbury Laboratory SRS (25 369 reflections in the resolution range 20–2.5 Å) and reduced using HKL2000 (HKL Research Inc) (Table 1). The solvent content of the crystals suggests that each contains a dimer. To be consistent with a tetrameric state, this requires a twofold symmetry axis of the tetramer to be coincident with a twofold crystallographic axis and the remaining twofold symmetry axes to be non-crystallographic.
|
Acknowledgements
The authors would like to thank David Hopwood for the gift of S. coelicolor genomic DNA.
References
Crump, M. P., Crosby, J., Dempsey, C. E., Parkinson, J. A., Murray, M., Hopwood, D. A. & Simpson, T. J. (1997). Biochemistry, 36, 6000–6008. CrossRef CAS PubMed Web of Science Google Scholar
Findlow, S. C., Winsor, C., Simpson, T. J., Crosby, J. & Crump, M. P. (2003). Biochemistry, 42, 8423–8433. Web of Science CrossRef PubMed CAS Google Scholar
Fu, H., Ebert-Khosla, S., Hopwood, D. A. & Khosla, C. (1994). J. Am. Chem. Soc. 116, 4166–4170. CrossRef CAS Web of Science Google Scholar
Fu, H., McDaniel, R., Hopwood, D. A. & Khosla, C. (1994a). Biochemistry, 33, 9321–9326. CrossRef CAS PubMed Web of Science Google Scholar
Fu, H., McDaniel, R., Hopwood, D. A. & Khosla, C. (1994b). Chem. Biol. 1, 205–210. CrossRef CAS PubMed Google Scholar
Hopwood, D. A. (1990). Annu. Rev. Genet. 24, 37–66. CrossRef CAS PubMed Google Scholar
Hopwood, D. A. (1997). Chem. Rev. 97, 2465–2497. CrossRef PubMed CAS Web of Science Google Scholar
Jornvall, H., Persson, B., Krook, M., Atrian, S., Gonzalezduarte, R., Jeffery, J. & Ghosh, D. (1995). Biochemistry, 34, 6003–6013. CrossRef CAS PubMed Google Scholar
Kallberg, Y., Oppermann, U., Jornvall, H. & Persson, B. (2002). Protein Sci. 11, 636–641. Web of Science CrossRef PubMed CAS Google Scholar
Li, Q., Khosla, C., Puglisi, J. D. & Liu, C. W. (2003). Biochemistry, 42, 4648–4657. Web of Science CrossRef PubMed CAS Google Scholar
McDaniel, R., Ebert-Khosla, S., Fu, H., Hopwood, D. A. & Khosla, C. (1994). Proc. Natl Acad. Sci. USA, 91, 11542–11546. CrossRef CAS PubMed Web of Science Google Scholar
McDaniel, R., Ebert-Khosla, S., Hopwood, D. A. & Khosla, C. (1995). Nature (London), 375, 549–554. CrossRef CAS PubMed Web of Science Google Scholar
Oppermann, U., Filling, C., Hult, M., Shafqat, N., Wu, X. Q., Lindh, M., Shafqat, J., Nordling, E., Kallberg, Y., Persson, B. & Jornvall, H. (2003). Chem. Biol. Interact. 143, 247–253. Web of Science CrossRef PubMed Google Scholar
Oppermann, U. C. T., Filling, C. & Jornvall, H. (2001). Chem. Biol. Interact. 130, 699–705. Web of Science CrossRef PubMed Google Scholar
Pan, H., Tsai, S. C., Meadows, E. S., Miercke, L. J. W., Keatinge-Clay, A. T., O'Connell, J., Khosla, C. & Stroud, R. M. (2002). Structure, 10, 1559–1568. Web of Science CrossRef PubMed CAS Google Scholar
Staunton, J. & Weissman, K. J. (2001). Nat. Prod. Rep. 18, 380–416. Web of Science CrossRef PubMed CAS Google Scholar
© International Union of Crystallography. Prior permission is not required to reproduce short quotations, tables and figures from this article, provided the original authors and source are cited. For more information, click here.